VisVires New Protein 

VisVires New Protein (VVNP) is a venture capital fund that aims to achieve outsize returns from focused investments on disruptive technologies for the food and feed system.

Today’s life sciences and new technologies deliver opportunities to redesign the food supply system from the ground up.
We focus our investments on companies which bring pioneering solutions to key food-related issues, along the whole supply chain. Biotechnology, data sciences, as well as automation and novel processes, will be crucial to sustainable animal feed, green aquaculture and innovative human food product development.

Food and feed, the next frontier

VVNP was created on the premises that the foreseeable shortage in animal protein would spur the development of innovative solutions and generate opportunities to invest. But the stakes are even higher. Today, in an arguably more complex food ecosystem, we see many factors driving the need to comprehensively rethink the whole food production and supply chain: globalization of agriculture and animal farming, changes in dietary habits in developing countries, impact of climate change, the multiple causes and issues of food waste, as well as consumer demand for healthier food propositions.

The commitment to innovation

We are strongly committed to innovation. Old models of food production will have to be replaced by new solutions. A more scientific approach will be crucial to provide solutions for the long term. Tomorrow our resources will diminish while our technological skills  will increase. Some technological advancements are particularly timely to address the above challenges. They can  give life to disruptive models and provide transformational services. This offers a whole breadth of opportunities to investors.

Bringing in innovation and capital, VVNP is building a portfolio of outstanding companies with creative, scientifically rigorous and delivery-focused management teams.

We invest in companies at early stages of their development, from angel all the way to series B.



Addressing the foreseeable shortage of

animal protein

Our agricultural model has not yet evolved to face the challenges brought by a growing population with changing diets.
Innovation will help make animal farming more sustainable, and novel processes will develop scalable new sources of protein.


Leveraging an increased understanding of

food and health interaction 

Over the past few decades, food has contributed to exacerbate a number of metabolic and chronic diseases.
The start ups we are looking at are working on making food a solution, not a problem.


Building a safer food chain

whilst reducing waste

More than a third of the food produced is wasted along the food chain in both developed and developing countries.
Improving food safety practices, producing closer to the consumer, reusing waste, creating sustainable packaging are many ways to reduce spoilage. 


Who we are



marie anne.jpg







Darren_head_photo_bg (1).jpg


WhatsApp Image 2018-06-21 at 12.50.24.jpeg


Matthieu Vermersch .  

Matthieu has over 25 years of experience in investment management with a concentration on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.
Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees.
Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.
Matthieu has a postgraduate degree in Corporate Finance from Universite Paris Dauphine and has a graduate degree from Institut d'Etudes Politiques de Paris (Sciences Po). 

Marie-Anne Dupin-Vermersch

Marie-Anne has acquired a diverse professional background managing non-profit as well as for profit projects in Africa, Indonesia and Singapore with a strong emphasis on environmentally friendly ventures. She has spent most of her professional life between Asia and the USA. Marie-Anne has an extensive knowledge of the major issues facing food and feed industries today.  She is driving our research efforts and makes sure our investment scope stays within the sustainable and scalable boundaries. Marie-Anne is passionate about finding solutions for these pressing global problems. 
She has a double major in Law and Chinese Language and Civilization.

Thibaut Mercey

Based in Paris' Station F, the biggest startup campus in the world, Thibaut supports the investment team in deal structuring and execution. He brings over 16 years experience in the field of innovation and entrepreneurship.
Prior to VVNP, he was a serial entrepreneur co-founding three 3 high-tech start-ups in the field of life sciences.
Thibaut has been named among the 10 Best French Innovators Under 35 by MIT Technology Review (2013).
He holds a MSc from Institut d’Optique Graduate School and an MBA from London Business School with a major in Entrepreneurial Management. 

Gerard Chia 

Gerard heads the fund's business development efforts and supports the investment team.
Most recently, Gerard was the right-hand to the former Chairman of the holding co. of the Firmenich Group, where he was Head of Special Projects. Previously, he was an Investment Analyst with Saratoga Capital, an Indonesia-focused private equity fund.
Gerard has a graduate degree in Banking and Finance from University of London International Programme (LSE).

Candice Gomes

Candice is part of the portfolio management team of VVNP.  
Prior to this, she was an investment manager with Singapore Technologies Telemedia. She previously was the deputy head of the Product Management team of Partners Group, before serving as an assistant vice president with Keppel. 
Candice has a B.Sc (Life Sciences) from the National University of Singapore, a Master in Finance from the University of Wales, and is currently pursuing her Doctorate with Manchester Business School.

Darren Leong

Darren is part of the deal-sourcing team at VVNP.
Previously, he worked for Sequoia-backed, SmartKarma, where he researched on upcoming IPO companies across multiple industries in the Asia-Pacific region. Prior to that, he had spent a year in Beijing, working for one of China's largest technology companies.
Darren graduated from Nanyang Technological University of Singapore with a Bachelors in Banking and Finance.

Noemie Bernard-Legall

Noemie supports the deal sourcing team with sector analytics. 
Prior to this, she worked with one of the world's largest personal care company, focusing on establishing product testings and protocols.
Noemie is a master student with France’s top life sciences school, AgroParisTech.

As of 1st Sept. 2016, New Protein Capital operates as a division of VisVires Capital whose team biographies can be found here.

Our location

Our firm is strategically based in Singapore, Southeast Asia's research and development hub, which also offers easy access to the greater Asia region. From here we can identify new markets and monitor important new developments in traditional agriculture and aquaculture industries. Singapore is also home to a myriad of scientific research centres and large food-related businesses.

With its receptiveness to new technologies and focus on research, the city is an attractive location for research talents and is a great place for ground-breaking innovation.




We are an early investor in YNSECT, a startup that produces insect meal, an environmentally sustainable alternative to fishmeal. This is ground-breaking as the price of fishmeal has already tripled in the last 10 years. YNSECT also produces extensive green chemistry products. We applaud its effective use of robotics and advanced engineering to rear insects at an unprecedented large scale.

YNSECT was created in 2011 by four partners (Antoine Hubert, Jean-Gabriel Levon, Fabrice Berro and Alexis Angot). Today, with their demo plant in Jura, France, they manage the world's largest fully-automated insect rearing facility.  


VisVires New Protein is the lead investor in Dublin-based startup Nuritas. The company was founded by Dr. Nora Khaldi, a mathematician with a PhD in Molecular Evolution and Bioinformatics to revolutionize the discovery of novel, natural and scientifically proven active ingredients that promote and manage our health.

The company’s disruptive computational approach to discovery uses artificial intelligence and DNA analysis to, for the first time ever, rapidly and efficiently provide access to the most health-benefiting components within food called peptides. Nuritas’s patented life-changing peptides provide unique solutions for the maintenance of health and wellness. These benefits include: anti-inflammatory activity, antimicrobial activity, muscle recovery enhancement, skin anti-aging solutions, and the potential management of blood sugar levels for type 2 diabetics. Put in a nutshell, the company discovers and unlocks ingredients from food sources in a completely unique way, providing natural, safe and sustainable health solutions.




We would love to hear about your investment opportunity.
To better appreciate the opportunity, we would like to know:

·       the type of products or services you are developing
·       the industries and markets you intend to address
·       why do you think that your proposition is innovative and will have an impact on the foreseeable protein shortage

We understand that the privacy of all information you provide is of primary importance and are committed to ensuring the ethical treatment and safeguarding of confidential information.




110 Amoy Street, Level 2
069930 Singapore

+(65) 6817 3765